An official website of the United States government
          Here’s how you know
        Here’s how you know**Official websites use .gov**A
              **.gov** website belongs to an official government
              organization in the United States.
        **Secure .gov websites use HTTPS**A
              **lock** (
              Locked padlock icon) or **https://** means you’ve safely connected to the .gov website. Share sensitive information only on official, secure websites.
 Top Utility Nav
        
        
        Asian-Language Resources
        
        Portal en español


Site search Mega Menu
  

        

        Home
                  Health Topics
                                      
    
  Health Topics

    Arthritis and Rheumatic Diseases
          
    Muscle and Bone Diseases
          
    Skin Diseases
          
    All Diseases and Conditions
          
    Publication Catalog
                  Grants & Funding
                                      
    
  Grants & Funding

    Current Funding Opportunities
          
    Supported Scientific Programs
          
    NIAMS-Supported Programs
          
    Applying for a Grant
          
    NIH Policies and Guidance
          
    Peer Review and Grants Administration Resources
          
    Types of Funding Mechanisms (Activity Codes)
                  Labs @ NIAMS
                                      
    
  Labs @ NIAMS

    NIAMS Labs and Core Facilities
          
    Research Faculty
          
    Research Areas
          
    NIAMS Scientific Advances
          
    Training and Career Development
                  Clinical Trials
                                      
    
  Clinical Trials
      
            For Principal Investigators

    Clinical Trial Policies, Guidelines, and Templates
          
    Conducting Clinical Trials
          
    Register with ClinicalTrials.gov

For Patients

What is a Clinical Trial?
	Clinical Trials at NIAMS
	Clinical Trials in the Spotlight
                  News & Events
                                      
    
  Newsroom

    All NIAMS News
          
    NIAMS Newsletters
          
    Meetings & Events
                  About NIAMS
                                      
    
  About NIAMS

    Director's Page
          
    NIAMS Organization
          
    Strategic Plan Fiscal Years 2020-2024
          
    Staff Directory
          
    NIAMS Budget
          
    Partnerships
          
    Contact NIAMS
                  Community Outreach
                                      
    
  Community Outreach

    Bone Health
          
    Joint Health
          
    Muscle, Tendon, and Ligament Health
          
    Skin Health
          
    Health Information For Kids And Young Adults
          
    Health Information For Older Adults/Seniors
          
    Printable Materials for Community Events
          
    Resources in Other Languages
          
    Annual Health Observances
          
    Social Media Resources Breadcrumb
    Home
          About NIAMS
          Hanna Kim, M.S., M.D.





Hanna Kim, M.S., M.D.


Assistant Clinical Investigator
    Head, Juvenile Myositis Pathogenesis and Therapeutics Unit Image
              Hanna Kim, M.S., M.D. 
            Contact Information

                                                  301-594-6196
                
                                                9000 Rockville Pike
                  
            10 Center Drive
      
                  
            Building 10, Room 12S-257a
      
                                   Bethesda MD 20892
                
                                                hanna.kim@nih.gov 
                                          Media Resources
                                  
            High Resolution Image 
                Summary
          Hanna Kim, M.S., M.D., is a board-certified pediatric rheumatologist who is focused on exploring pathogenesis and novel treatments in juvenile dermatomyositis. During her rheumatology fellowship, Dr. Kim developed a passion for clinical and translational research while studying interferon-mediated autoinflammatory diseases, novel biomarkers, pharmacokinetics, and pharmacodynamics, and safety and efficacy in a compassionate use study with an investigational drug. She went on to become a Lawrence Shulman Scholar and studied the role of interferon and activity-related biomarkers in myositis, particularly juvenile dermatomyositis. She has also been evaluating Janus kinase inhibition in a compassionate use program for refractory juvenile dermatomyositis.

Dr. Kim was appointed as an Assistant Clinical Investigator in 2020 and is also an attending physician on the NIH Pediatric Rheumatology Consultation Service. She is actively involved in a range of organizations including the American College of Rheumatology (ACR), the Childhood Arthritis Rheumatology Research Alliance, and the International Myositis Assessment and Clinical Studies Group.

She has received numerous local, national, and international awards and honors, including NIAMS Group Merit Award, ACR Distinguished Fellow Award, Rheumatology Research Foundation Pediatric Research Award, Pediatric Rheumatology European Society Young Investigator Travel Award, selection for the ACR-European League Against Rheumatism Early Investigator Exchange Program, and best abstract at the Global Conference on Myositis. Dr. Kim has also given national and international presentations.
        
                  Research Statement
          
            The Juvenile Myositis Therapeutic and Translational Studies Unit is a research group focused on better understanding the pathogenesis of juvenile myositis, particularly inflammatory and immune mechanisms, and improved therapy. This is approached by discovery biomarker analysis utilizing broad expression such as transcriptomic and proteomic analysis in juvenile dermatomyositis, a rare autoimmune system vasculopathy with notable involvement of skin with characteristic rashes and muscle inflammation.  Another approach is looking at how biomarkers in juvenile myositis compare to Mendelian autoinflammatory disease and further analysis of juvenile myositis separated by myositis autoantibody subgroups which have some distinct patterns of features.

Regarding treatment, we investigate novel treatments in small clinical trials in juvenile myositis with the goal of establishing more targeted therapy ideally with fewer side-effects and greater efficacy.  We hope that through better understanding pathogenesis can be paired with the investigation of novel therapies that can lead to better management and improved quality of life for people with juvenile myositis. 

            Scientific Publications
              Insights into juvenile myositis via engineered muscle.

    Kim H
        

                    Nat Rev Rheumatol.
        
                    2023 Sep;
        
                    19(9).
        
                    doi: 10.1038/s41584-023-01003-6
                            PMID: 37495869
  Improvement in Disease Activity in Refractory Juvenile Dermatomyositis Following Abatacept Therapy.

    Curiel RV, Nguyen W, Mamyrova G, Jones D, Ehrlich A, Brindle KA, Haji-Momenian S, Sheets R, Kim H, Jones OY, Rider LG, Abatacept in Dermatomyositis (AID) Trial Investigators
        

                    Arthritis Rheumatol.
        
                    2023 Jul;
        
                    75(7).
        
                    doi: 10.1002/art.42450
                            PMID: 36657109
  Performance of the 2016 ACR-EULAR Myositis Response Criteria in adult dermatomyositis/polymyositis therapeutic trials and consensus profiles.

    Saygin D, Kim H, Douglas C, Erman B, Wilkerson J, McGrath JA, Oddis CV, Lundberg IE, Amato AA, García-De La Torre I, Chinoy H, Fiorentino D, Chung L, Song YW, Miller FW, Ruperto N, Vencovsky J, Aggarwal R, Rider LG, International Myositis Assessment and Clinical Studies Group (IMACS)
        

                    Rheumatology (Oxford).
        
                    2023 Nov 2;
        
                    62(11).
        
                    doi: 10.1093/rheumatology/kead110
                            PMID: 36929923
  Performance of the 2016 ACR-EULAR myositis response criteria in juvenile dermatomyositis therapeutic trials and consensus profiles.

    Kim H, Saygin D, Douglas C, Wilkerson J, Erman B, Pistorio A, McGrath JA, Reed AM, Oddis CV, Bracaglia C, van Royen-Kerkhof A, Bica B, Dolezalova P, Ferriani VPL, Flato B, Bernard-Medina AG, Herlin T, Miller FW, Vencovsky J, Ruperto N, Aggarwal R, Rider LG, International Myositis Assessment and Clinical Studies Group (IMACS) and Paediatric Rheumatology INternational Trials Organization (PRINTO)
        

                    Rheumatology (Oxford).
        
                    2023 Nov 2;
        
                    62(11).
        
                    doi: 10.1093/rheumatology/kead111
                            PMID: 36929918
  Urine proteomics by mass spectrometry identifies proteins involved in key pathogenic pathways in patients with juvenile dermatomyositis.

    Morales M, Alayi TD, Tawalbeh SM, Sydenstricker AV, Spathis R, Kim H, Nagaraju K, Hathout Y, Rider LG
        

                    Rheumatology (Oxford).
        
                    2023 Sep 1;
        
                    62(9).
        
                    doi: 10.1093/rheumatology/kead033
                            PMID: 36661295
  Improvement in Disease Activity in Refractory Juvenile Dermatomyositis Following Abatacept Therapy.

    Curiel RV, Nguyen W, Mamyrova G, Jones D, Ehrlich A, Brindle KA, Haji-Momenian S, Sheets R, Kim H, Jones OY, Rider LG, Abatacept in Dermatomyositis (AID) Trial Investigators
        

                    Arthritis Rheumatol.
        
                    2023 Jul;
        
                    75(7).
        
                    doi: 10.1002/art.42450
                            PMID: 36657109
  Treatment escalation patterns to start biologics in refractory moderate juvenile dermatomyositis among members of the Childhood Arthritis and Rheumatology Research Alliance.

    Sherman MA, Kim H, Banschbach K, Brown A, Gewanter HL, Lang B, Perron M, Robinson AB, Spitznagle J, Stingl C, Syverson G, Tory HO, Spencer CH, Tarvin SE
        

                    Pediatr Rheumatol Online J.
        
                    2023 Jan 6;
        
                    21(1).
        
                    doi: 10.1186/s12969-022-00785-5
                            PMID: 36609397
  Updates on Juvenile Dermatomyositis from the Last Decade: Classification to Outcomes.

    Kim H, Huber AM, Kim S
        

                    Rheum Dis Clin North Am.
        
                    2021 Nov;
        
                    47(4).
        
                    doi: 10.1016/j.rdc.2021.07.003
                            PMID: 34635298
  Updates on interferon in juvenile dermatomyositis: pathogenesis and therapy.

    Kim H
        

                    Curr Opin Rheumatol.
        
                    2021 Sep 1;
        
                    33(5).
        
                    doi: 10.1097/BOR.0000000000000816
                            PMID: 34230439
  Janus kinase (JAK) inhibition with baricitinib in refractory juvenile dermatomyositis.

    Kim H, Dill S, O'Brien M, Vian L, Li X, Manukyan M, Jain M, Adeojo LW, George J, Perez M, Grom AA, Sutter M, Feldman BM, Yao L, Millwood M, Brundidge A, Pichard DC, Cowen EW, Shi Y, Lu S, Tsai WL, Gadina M, Rider LG, Colbert RA
        

                    Ann Rheum Dis.
        
                    2021 Mar;
        
                    80(3).
        
                    doi: 10.1136/annrheumdis-2020-218690
                            PMID: 32843325
  Expression of interferon-regulated genes in juvenile dermatomyositis versus Mendelian autoinflammatory interferonopathies.

    Kim H, Gunter-Rahman F, McGrath JA, Lee E, de Jesus AA, Targoff IN, Huang Y, O'Hanlon TP, Tsai WL, Gadina M, Miller FW, Goldbach-Mansky R, Rider LG
        

                    Arthritis Res Ther.
        
                    2020 Apr 6;
        
                    22(1).
        
                    doi: 10.1186/s13075-020-02160-9
                            PMID: 32252809
  Development of a Validated Interferon Score Using NanoString Technology.

    Kim H, de Jesus AA, Brooks SR, Liu Y, Huang Y, VanTries R, Montealegre Sanchez GA, Rotman Y, Gadina M, Goldbach-Mansky R
        

                    J Interferon Cytokine Res.
        
                    2018 Apr;
        
                    38(4).
        
                    doi: 10.1089/jir.2017.0127
                            PMID: 29638206
  Pharmacokinetics, Pharmacodynamics, and Proposed Dosing of the Oral JAK1 and JAK2 Inhibitor Baricitinib in Pediatric and Young Adult CANDLE and SAVI Patients.

    Kim H, Brooks KM, Tang CC, Wakim P, Blake M, Brooks SR, Montealegre Sanchez GA, de Jesus AA, Huang Y, Tsai WL, Gadina M, Prakash A, Janes JM, Zhang X, Macias WL, Kumar P, Goldbach-Mansky R
        

                    Clin Pharmacol Ther.
        
                    2018 Aug;
        
                    104(2).
        
                    doi: 10.1002/cpt.936
                            PMID: 29134648
  JAK1/2 inhibition with baricitinib in the treatment of autoinflammatory interferonopathies.

    Sanchez GAM, Reinhardt A, Ramsey S, Wittkowski H, Hashkes PJ, Berkun Y, Schalm S, Murias S, Dare JA, Brown D, Stone DL, Gao L, Klausmeier T, Foell D, de Jesus AA, Chapelle DC, Kim H, Dill S, Colbert RA, Failla L, Kost B, O'Brien M, Reynolds JC, Folio LR, Calvo KR, Paul SM, Weir N, Brofferio A, Soldatos A, Biancotto A, Cowen EW, Digiovanna JJ, Gadina M, Lipton AJ, Hadigan C, Holland SM, Fontana J, Alawad AS, Brown RJ, Rother KI, Heller T, Brooks KM, Kumar P, Brooks SR, Waldman M, Singh HK, Nickeleit V, Silk M, Prakash A, Janes JM, Ozen S, Wakim PG, Brogan PA, Macias WL, Goldbach-Mansky R
        

                    J Clin Invest.
        
                    2018 Jul 2;
        
                    128(7).
        
                    doi: 10.1172/JCI98814
                            PMID: 29649002
  Biologic therapies for refractory juvenile dermatomyositis: five years of experience of the Childhood Arthritis and Rheumatology Research Alliance in North America.

    Spencer CH, Rouster-Stevens K, Gewanter H, Syverson G, Modica R, Schmidt K, Emery H, Wallace C, Grevich S, Nanda K, Zhao YD, Shenoi S, Tarvin S, Hong S, Lindsley C, Weiss JE, Passo M, Ede K, Brown A, Ardalan K, Bernal W, Stoll ML, Lang B, Carrasco R, Agaiar C, Feller L, Bukulmez H, Vehe R, Kim H, Schmeling H, Gerstbacher D, Hoeltzel M, Eberhard B, Sundel R, Kim S, Huber AM, Patwardhan A, Pediatric Rheumatologist Collaborators
        

                    Pediatr Rheumatol Online J.
        
                    2017 Jun 13;
        
                    15(1).
        
                    doi: 10.1186/s12969-017-0174-0
                            PMID: 28610606
  Insights from Mendelian Interferonopathies: Comparison of CANDLE, SAVI with AGS, Monogenic Lupus.

    Kim H, Sanchez GA, Goldbach-Mansky R
        

                    J Mol Med (Berl).
        
                    2016 Oct;
        
                    94(10). 
          Education
              
            **University of California at Irvine (UCI)**
M.D.

**Virginia Commonwealth University (VCU)**
M.S.

**California Institute of Technology (Caltech)**
B.S.             
                        Experience
              
            **Lawrence Shulman Scholar in Translational Research**
NIAMS, NIH, Bethesda, MD

**Residency in Pediatrics**
George Washington University / Children’s National Medical Center

**Pediatric Rheumatology Fellowship**
Nemours/Alfred I. DuPont Hospital for Children (Wilmington, DE), Children’s National Health System (DC), and NIAMS, NIH.


Last Updated: August 2023


Back to Top
 About NIAMS
                    Clinical Trials
                    Grants & Funding
                    Health Topics
                    Labs @ NIAMS
              News Room
                    NIAMS Multimedia Library
                    Disclaimer
                    FOIA
                    Contact us
              Privacy Statement
                    Accessibility
                    HHS Vulnerability Disclosure
                    Social Media Moderation Policy
                    NIAMS Archives
        Subscribe to Our E-Newsletters
            Click the button to see different options to sign up for newsletters.
            Click Here to Subscribe
          Follow us on
  
  About NIH
                  Accessibility Support
            FOIA requests
                  No FEAR Act data
            Office of the Inspector General
                  Performance reports
            Privacy Policy